OncoMatch

OncoMatch/Clinical Trials/NCT06377371

Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE

Is NCT06377371 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies non-drug interventions for meningioma.

Phase 4RecruitingWeill Medical College of Cornell UniversityNCT06377371Data as of May 2026

The study team hypothesizes that it is feasible to intraoperatively detect tumor following \[CU64\]DOTATATE injection using the gamma probe device.

Check if I qualify

Extracted eligibility criteria

Prior therapy

Cannot have received: radiation therapy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • New York-Presbyterian/Weill Cornell Medical Center · New York, New York

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify